Clinical Trial: Efficacy and Safety of SBRT Combined With Becotatug Vedotin in EGFR-Positive Metastatic Tumor Patients With Oligometastases

U.S., March 20 -- ClinicalTrials.gov registry received information related to the study (NCT07481799) titled 'Efficacy and Safety of SBRT Combined With Becotatug Vedotin in EGFR-Positive Metastatic Tumor Patients With Oligometastases' on March 15.

Brief Summary: The combination of local consolidative treatment for oligometastases and systemic therapy offers the potential for clinical cure and significantly prolongs survival in a subset of patients with advanced metastatic disease. However, a considerable number of patients still do not benefit from this approach. Becotatug vedotin is an antibody-drug conjugate that carries the payload Monomethyl auristatin E (MMAE), a microtubule inhibitor. In various preclinical tumor models, including he...